• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY: TAK )

    13.10 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    17 18 Next >
    Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
    This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
    Via Benzinga
    Why Puma Biotechnology's Shares Jumped 20% on Monday
    It may have benefited from positive news about another company's drug candidate. 
    Via The Motley Fool
    Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
    Via Benzinga
    Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
    Via Benzinga
    Stocks That Hit 52-Week Lows On Wednesday
      On Wednesday, 200 companies hit new 52-week lows. 
    Via Benzinga
    Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
    Via Benzinga
    Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
    Is now the time to load up on these high-yielding investments? 
    Via The Motley Fool
    European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
    The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close. 
    Via The Motley Fool
    Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    7 Dividend Stocks to Sell Pronto Before a Painful Downturn
    Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield. 
    Via InvestorPlace
    CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
    Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
    Via Investor's Business Daily
    Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Earnings Scheduled For October 27, 2022
    Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
    Via Benzinga
    3 High-Yielding Dividend Stocks Near Their 52-Week Lows
    These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%. 
    Via The Motley Fool
    Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
    FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
    Via FinancialNewsMedia
    Topics Cannabis
    Exposures Cannabis
    U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
    Via Benzinga
    Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
    Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
    Via Investor's Business Daily
    Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    7 Stocks Under $15 to Buy and Hold Forever
    For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul. 
    Via InvestorPlace
    Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
    The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of... 
    Via Benzinga
    With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
    Via Benzinga
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 13
    ...
    17 18 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.